IBDEI1ZY ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33879,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,33880,0)
 ;;=C82.39^^131^1680^70
 ;;^UTILITY(U,$J,358.3,33880,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33880,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,33880,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,33880,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,33881,0)
 ;;=C82.30^^131^1680^71
 ;;^UTILITY(U,$J,358.3,33881,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33881,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,33881,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,33881,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,33882,0)
 ;;=C82.49^^131^1680^72
 ;;^UTILITY(U,$J,358.3,33882,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33882,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,33882,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,33882,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,33883,0)
 ;;=C82.40^^131^1680^73
 ;;^UTILITY(U,$J,358.3,33883,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33883,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,33883,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,33883,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,33884,0)
 ;;=C82.99^^131^1680^74
 ;;^UTILITY(U,$J,358.3,33884,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33884,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,33884,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,33884,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,33885,0)
 ;;=C82.90^^131^1680^75
 ;;^UTILITY(U,$J,358.3,33885,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33885,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,33885,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,33885,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,33886,0)
 ;;=R59.1^^131^1680^60
 ;;^UTILITY(U,$J,358.3,33886,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33886,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,33886,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,33886,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,33887,0)
 ;;=C91.40^^131^1680^79
 ;;^UTILITY(U,$J,358.3,33887,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33887,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,33887,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,33887,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,33888,0)
 ;;=C91.42^^131^1680^77
 ;;^UTILITY(U,$J,358.3,33888,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33888,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,33888,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,33888,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,33889,0)
 ;;=C91.41^^131^1680^78
 ;;^UTILITY(U,$J,358.3,33889,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33889,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,33889,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,33889,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,33890,0)
 ;;=D57.01^^131^1680^80
 ;;^UTILITY(U,$J,358.3,33890,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33890,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,33890,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,33890,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,33891,0)
 ;;=D57.00^^131^1680^81
 ;;^UTILITY(U,$J,358.3,33891,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33891,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,33891,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,33891,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,33892,0)
 ;;=D57.02^^131^1680^82
 ;;^UTILITY(U,$J,358.3,33892,1,0)
 ;;=^358.31IA^4^2
